Tazverik™ (tazemetostat) – New orphan drug approval
January 23, 2020 - The FDA announced the approval of Epizyme’s Tazverik (tazemetostat), for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.
Top